Literature DB >> 24637070

Bile duct evaluation of potential living liver donors with Gd-EOB-DTPA enhanced MR cholangiography: Single-dose, double dose or half-dose contrast enhanced imaging.

Sonja Kinner1, Verena Steinweg2, Stefan Maderwald3, Arnold Radtke4, Georgios Sotiropoulos4, Michael Forsting2, Tobias Schroeder2.   

Abstract

INTRODUCTION: Detailed knowledge of the biliary anatomy is essential to avoid complications in living donor liver transplantation. The aim of this study was to determine the optimal dosage of Gd-EOB-DTPA for contrast-enhanced magnetic resonance cholangiography (ce-MRC) with reference to contrast-enhanced CT cholangiography (ce-CTC).
MATERIALS AND METHODS: 30 potential living liver donors (PLLD) underwent both ce-CTC and ce-MRC. Ten candidates each received single, double or half-dose Gd-EOB-DTPA. Ce-MRC images with and without inversion recovery pulses (T1w±IR) were acquired 20-30min after intravenous contrast injection. Image data was quantitatively and qualitatively reviewed by two radiologists based on a on a 5-point scale. Data sets were compared using a Mann-Whitney-U-test or Wilcoxon-rank-sum-test. Kappa values were also calculated.
RESULTS: All image series provided sufficient diagnostic information both showing normal biliary anatomy and variant bile ducts. Ce-CTC showed statistically significant better results compared to all ce-MRC data sets. T1w MRC with single dose Gd-EOB-DTPA proved to be superior to half and double dose in subjective and objective evaluation without a statistically significant difference.
CONCLUSIONS: Ce-MRC is at any dosage inferior to ce-CTC. As far as preoperative planning of bile duct surgery is focused on the central biliary anatomy, ce-MRC can replace harmful ce-CTC strategies, anyway. Best results were seen with single dose GD-EOB-DTPA on T1w MRC+IR.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Gd-EOB-DTPA,; Living liver transplantation; MR cholangiography

Mesh:

Substances:

Year:  2014        PMID: 24637070     DOI: 10.1016/j.ejrad.2014.02.012

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Added value of gadoxetic acid-enhanced T1-weighted magnetic resonance cholangiography for the diagnosis of post-transplant biliary complications.

Authors:  Sonja Kinner; Tilman B Schubert; Adnan Said; Joshua D Mezrich; Scott B Reeder
Journal:  Eur Radiol       Date:  2017-04-13       Impact factor: 5.315

2.  The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green.

Authors:  Hiroyuki Akai; Koichiro Yasaka; Akira Kunimatsu; Masanori Nojima; Yusuke Inoue; Osamu Abe; Kuni Ohtomo; Shigeru Kiryu
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

3.  Coronal 2D MR cholangiography overestimates the length of the right hepatic duct in liver transplantation donors.

Authors:  Bohyun Kim; Kyoung Won Kim; So Yeon Kim; So Hyun Park; Jeongjin Lee; Gi Won Song; Dong-Hwan Jung; Tae-Yong Ha; Sung Gyu Lee
Journal:  Eur Radiol       Date:  2016-09-05       Impact factor: 5.315

Review 4.  Intravenous gadolinium-based hepatocyte-specific contrast agents (HSCAs) for contrast-enhanced liver magnetic resonance imaging in pediatric patients: what the radiologist should know.

Authors:  Rama S Ayyala; Sudha A Anupindi; Michael S Gee; Andrew T Trout; Michael J Callahan
Journal:  Pediatr Radiol       Date:  2019-07-26

5.  Non-Contrast-Enhanced and Contrast-Enhanced Magnetic Resonance Angiography in Living Donor Liver Vascular Anatomy.

Authors:  Chien-Chang Liao; Meng-Hsiang Chen; Chun-Yen Yu; Leung-Chit Leo Tsang; Chao-Long Chen; Hsien-Wen Hsu; Wei-Xiong Lim; Yi-Hsuan Chuang; Po-Hsun Huang; Yu-Fan Cheng; Hsin-You Ou
Journal:  Diagnostics (Basel)       Date:  2022-02-15

6.  Oral effervescent agent improving magnetic resonance cholangiopancreatography.

Authors:  Heon-Ju Kwon; Kyoung Won Kim; Kyung A Kang; Mi Sung Kim; So Yeon Kim; Taeyong Park; Jeongjin Lee
Journal:  Quant Imaging Med Surg       Date:  2022-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.